Harvard Bioscience Inc.

Holliston biotechnology firm Harvard Bioscience continued its fourth quarter momentum with revenue up 14% in the first quarter of 2021 when compared to the first quarter of 2020.

Holliston biotechnology firm Harvard Bioscience returned to pre-COVID-19 revenue levels in the fourth quarter, but the company’s financial performance was still down overall for the year when compared to 2019.

Holliston’s Harvard Bioscience has continued to correct course in the third quarter of the year after a rocky start to the year saw the company lose $4.5-million loss in the first quarter, according to its earnings report from Wednesday.

Holliston’s Harvard Bioscience has returned on course in the second quarter after a rocky start to the year, where it had a $4.5-million loss in the first quarter, according to its earnings report from Wednesday.

Holliston’s Harvard Bioscience announced it had a $3.3-million operating loss in the first quarter of the year and predicted year-over-year losses would continue into the second quarter of the year.

Three public companies in Central Massachusetts have disclosed they received a combined $8.4 million in federal loans for the program intended to bailout small businesses.

Holliston-based Harvard Bioscience announced Thursday that Susan Steele has been appointed to the company’s Board of Directors as a Class III director in a move to appease an activist investor company planning to nominate their own board member candidates.

Holliston biotechnology firm Harvard Bioscience, Inc. has developed a new technology to provide researchers with real-time access to aerosol amounts deposited inside subjects' lungs, the company said in a press release.

In its fourth-quarter earnings report released Wednesday, Holliston biotech Harvard Bioscience announced it has started a restructuring program expected to save about $4 million, including laying off workers and closing its facilities.

Harvard Bioscience of Holliston has hired Yash Singh as an executive vice president to lead the newly formed cellular and molecular technologies team for the Holliston company.